Healthcare provider profile · identity verified

Marie Lynn Kellett, MD

Family Practice · YORK, PA · NPI 1437181021

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	249	65
Lisinopril	Lisinopril	148	37
Omeprazole	Omeprazole	129	28
Gabapentin	Gabapentin	124	29
Albuterol Sulfate Hfa	Albuterol Sulfate	113	32
Levothyroxine Sodium	Levothyroxine Sodium	102	21
Metformin Hcl	Metformin Hcl	76	18
Meloxicam	Meloxicam	74	13
Amlodipine Besylate	Amlodipine Besylate	72	27
Furosemide	Furosemide	65	16
Trulicity	Dulaglutide	62	13
Ozempic	Semaglutide	61	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	57	13
Trazodone Hcl	Trazodone Hcl	55	12
Quetiapine Fumarate	Quetiapine Fumarate	52	suppressed
Potassium Chloride	Potassium Chloride	49	12
Simvastatin	Simvastatin	49	14
Metoprolol Succinate	Metoprolol Succinate	48	11
Rosuvastatin Calcium	Rosuvastatin Calcium	48	12
Losartan Potassium	Losartan Potassium	47	14
Pantoprazole Sodium	Pantoprazole Sodium	45	12
Atenolol	Atenolol	42	suppressed
Famotidine	Famotidine	41	12
Buspirone Hcl	Buspirone Hcl	39	suppressed
Alendronate Sodium	Alendronate Sodium	38	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Montelukast Sodium	Montelukast Sodium	37	suppressed
Baclofen	Baclofen	35	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	35	suppressed
Bupropion Xl	Bupropion Hcl	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	12
Oxycodone Hcl	Oxycodone Hcl	35	suppressed
Jardiance	Empagliflozin	33	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	12
Prednisone	Prednisone	31	15
Fludrocortisone Acetate	Fludrocortisone Acetate	28	suppressed
Carvedilol	Carvedilol	27	suppressed
Lorazepam	Lorazepam	27	suppressed
Diclofenac Sodium	Diclofenac Sodium	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Propranolol Hcl	Propranolol Hcl	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	13
Clopidogrel	Clopidogrel Bisulfate	23	suppressed
Sertraline Hcl	Sertraline Hcl	23	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	21	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	18	suppressed
Eliquis	Apixaban	18	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Glipizide Er	Glipizide	17	suppressed
Prazosin Hcl	Prazosin Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	16	suppressed
Lamotrigine	Lamotrigine	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	16	suppressed
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Naproxen	Naproxen	14	suppressed
Valsartan	Valsartan	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Guanfacine Hcl	Guanfacine Hcl	12	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	12	suppressed
Naltrexone Hcl	Naltrexone Hcl	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Pregabalin	Pregabalin	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error